PF-Atlas › Clinical Trials › NCT01385644
A Study to Evaluate the Potential Role of Mesenchymal Stem Cells in the Treatment of Idiopathic Pulmonary Fibrosis
Placental MSC · Phase 1
Registry ID
NCT01385644
Phase
Phase 1
Status
Completed
Drug / intervention
Placental MSC
Sponsor
The Prince Charles Hospital
Start
2010-10
Enrollment
8
Locations
1
About this trial
The primary objective of this study is to establish the feasibility and safety of infusions of placental Mesenchymal Stem Cells (MSC) from related or unrelated HLA identical or HLA mismatched donors in the treatment of Idiopathic Pulmonary Fibrosis (IPF). The secondary objectives are to document changes in lung function, 6 minute walk distance (6MWD), gas exchange and radiological appearance following infusion of MSC over a six month evaluation period.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT01385644 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.